Dr. Mikhail Fedyanin on Mutation Discordance in CRC

Mikhail Fedyanin, MD, PhD
Published: Wednesday, Oct 19, 2016


Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).
 
The concordance of mutational status between primary tumor and metastases in CRC is typically between 80 to 95%, says Fedyanin. But in his study they identified a high discordance status. This is connected to the time between primary tumor resection and metastasectomy, which is about 1 year.
 
Other studies investigating this same area also found mutation discordance in KRAS, NRAS, BRAF and other genes.
 
SELECTED
LANGUAGE

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).
 
The concordance of mutational status between primary tumor and metastases in CRC is typically between 80 to 95%, says Fedyanin. But in his study they identified a high discordance status. This is connected to the time between primary tumor resection and metastasectomy, which is about 1 year.
 
Other studies investigating this same area also found mutation discordance in KRAS, NRAS, BRAF and other genes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x